Our approach to heart disease involves a comprehensive understanding of the complexities associated with common diagnoses such as congestive heart failure, atherosclerotic heart disease, and stroke. We recognize that these conditions require specialized interventions, including medications and therapies to ensure the best possible quality of life for our patients.
CONGESTIVE HEART FAILURE
In the context of a terminal condition, CHF refers to advanced heart failure that is no longer responding in respect to curative interventions. As CHF progresses towards the end stages, the heart's ability to pump blood effectively becomes severely compromised. This leads to a buildup of fluid in the lungs and other parts of the body, resulting in symptoms such as:
- Severe fatigue and weakness
- Shortness of breath, even at rest or with minimal exertion
- Persistent coughing and wheezing
- Swelling (edema) in the legs, ankles, and abdomen
- Significant weight loss and muscle wasting
- Reduced ability to perform activities of daily living
- Recurrent hospitalizations due to exacerbations and complications
Patients may experience increased symptom burden, reduced functional capacity, and worsening quality of life. Despite optimal medical management, symptoms become challenging to control, and the focus of care shifts towards palliative measures aimed at maximizing comfort and quality of life.
Hospice Eligibility for CHF:
- Evidence of severe functional impairment, such as the inability to perform activities of daily living independently.
- Frequent hospitalizations or emergency room visits despite optimal medical management.
- Continued symptoms, such as severe dyspnea (shortness of breath) at rest or with minimal exertion, despite maximal treatment.
- Marked decline in overall health status, including significant weight loss, advanced frailty, and progressive decline despite treatment.
- Objective measures like a low ejection fraction (measure of heart's pumping ability) and worsening cardiac function despite medical interventions.
- Presence of other comorbidities that significantly impact prognosis and quality of life.
ATHEROSCLEROTIC HEART DISEASE
Atherosclerotic heart disease, also known as coronary artery disease (CAD), refers to the progressive narrowing and hardening of the coronary arteries supplying the heart muscle. In a terminal condition context, atherosclerotic heart disease typically refers to advanced disease that is no longer amenable to curative interventions. Common manifestations and characteristics include:
- Recurrent angina (chest pain) that may become more frequent, severe, and difficult to manage.
- Impaired heart function due to severe blockages in the coronary arteries, leading to reduced pumping capacity and increased risk of heart failure.
- Increased risk of acute myocardial infarction (heart attack) due to unstable plaques in the coronary arteries.
- Cardiac arrhythmias and conduction abnormalities.
- Reduced exercise tolerance and functional capacity.
- Progressive decline in overall cardiac function, leading to symptoms such as fatigue, shortness of breath, and limitations in daily activities.
In the terminal stage of atherosclerotic heart disease, patients may experience worsening symptoms, increased frequency of cardiac events, and reduced cardiac reserve. The focus of care shifts towards providing comfort, managing symptoms, and optimizing quality of life through palliative measures and end-of-life support.
Hospice Eligibility for Atherosclerotic Heart Disease:
- Evidence of advanced, severe, and symptomatic coronary artery disease that is unresponsive to curative interventions such as bypass surgery or stent placement.
- Continued angina (chest pain) and symptoms despite optimal medical management.
- Recurrent hospitalizations or emergency room visits due to complications of atherosclerotic heart disease, such as myocardial infarctions (heart attacks).
- Significant functional impairment and limitations in activities of daily living due to the impact of atherosclerotic heart disease.
- Objective measures like severe left ventricular dysfunction or severe coronary artery disease that cannot be treated due to clinical reasons.
Hospice Eligibility for Stroke:
- Severe and irreversible neurological deficits resulting from a stroke, such as significant paralysis, loss of speech, or cognitive impairment.
- Dependence on others for activities of daily living due to stroke-related impairments.
- Continued decline in neurological function despite rehabilitation efforts.
- Recurrent strokes or complications related to the stroke, such as aspiration pneumonia or infections.
- Objective measures like a large and non-reversible infarct (area of tissue death) in a critical brain region that significantly affects function and prognosis.
MODALITIES AND THERAPIES
Medications:
a. Diuretics: Diuretics such as furosemide (Lasix) are often prescribed to manage fluid retention and reduce symptoms of congestion in congestive heart failure (CHF) patients.
b. Beta-blockers: Medications like metoprolol or carvedilol are frequently used in CHF and atherosclerotic heart disease to help control heart rate, blood pressure, and improve overall cardiac function.
c. Anticoagulants: For conditions like atherosclerotic heart disease and stroke, anticoagulant medications such as warfarin or direct oral anticoagulants (DOACs) may be prescribed to prevent blood clot formation and reduce the risk of further complications.
d. Analgesics: Pain management is an important aspect of hospice care. Nonsteroidal anti-inflammatory drugs (NSAIDs) or opioids may be used to alleviate chest pain or other discomfort associated with heart disease.
Oxygen Therapy:
In cases where patients experience difficulty breathing or have low oxygen levels, supplemental oxygen therapy may be provided to improve oxygenation and relieve symptoms.
LUNG FUNCTION AND HEART DISEASE
The connection between heart disease and lung disease can have a significant impact on the management of heart disease conditions in hospice care. Lung diseases, such as chronic obstructive pulmonary disease (COPD) or pulmonary fibrosis, can exacerbate heart disease and complicate the management of these conditions. Here's how it affects heart disease conditions under hospice:
Increased Cardiac Workload: Lung diseases can lead to reduced lung function and impaired oxygen exchange, resulting in lower oxygen levels in the blood. This places an additional burden on the heart, which has to work harder to deliver oxygen to the body's tissues. The increased workload on the heart can worsen symptoms and progression of heart disease, such as congestive heart failure (CHF).
Fluid Retention: In lung diseases like COPD, the compromised lung function can cause inadequate oxygen exchange and impair the removal of carbon dioxide. This can lead to an accumulation of carbon dioxide and acidosis, which can affect the heart's ability to pump effectively and contribute to fluid retention and exacerbation of CHF symptoms.
Medication Considerations: The management of heart disease in the presence of lung disease requires careful consideration of medications. Some medications commonly used to treat heart disease, such as beta-blockers, may have respiratory side effects and can exacerbate breathing difficulties in patients with lung disease. The selection and dosing of medications need to be individualized, taking into account the patient's lung function and respiratory status.
Oxygen Therapy: In cases of coexisting heart and lung disease, oxygen therapy becomes particularly crucial. It can help alleviate symptoms of both conditions by improving oxygenation and reducing the workload on the heart. Oxygen therapy may be used to manage low oxygen levels in the blood and relieve shortness of breath in patients with heart disease and lung disease.
Care Coordination: The management of heart disease and lung disease in hospice care requires close collaboration between healthcare professionals specializing in both cardiology and pulmonology. This interdisciplinary approach ensures that the complex needs of patients with both conditions are addressed comprehensively, and treatment plans are tailored to their individual circumstances.
—
Our agency's approach is rooted in compassionate care and a commitment to the overall well-being of patients with heart disease in hospice. We strive to alleviate symptoms, optimize comfort, and enhance the quality of life for our patients. Our team of healthcare professionals is trained to address the complexities of these conditions, and we continuously update our knowledge and practices to provide the best possible care.
